Nuvation Bio Inc.
corporate_fare Company Profile
Nuvation Bio Inc. (NYSE:NUVB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NUVB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for NUVB spans 10-Q, 8-K, 424B5, FWP.
Recent high-impact activity:
- IBTROZI Sales Hit $27.5M as Nuvation Bio Posts $45M Quarterly Revenue
- FDA Approves IBTROZI Label Update with 49.7-Month Duration of Response in ROS1+ NSCLC
- FDA Grants Fast Track to Nuvation Bio's Safusidenib for IDH1-Mutant Glioma
- Nuvation Bio Q2 Revenue Beats Estimates as IBTROZI Sales Jump 25%
- Nuvation Bio Q2 Revenue Beats Consensus, CEO Adopts 10b5-1 Plan, Pipeline Advances
Financial Snapshot
Short Interest & Short Volume
12.50 days to coverFINRA reported short interest of 61,999,741 shares in NUVB as of the October 30, 2026 settlement, a 1.9% decrease from the prior period — about 12.5 days to cover at its recent average daily volume. On November 20, 2026, 47.1% of NUVB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NUVB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-06.
Finalized Convertible Note Offering · Premium Conversion Price
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →